MENTAL QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS TREATED AND NON-TREATED WITH INTERFERON BETA-1B (IFNB-1B)
Languages of publication
In order to detect the influence of immunomodulatory treatment with interferon beta (IFNb) on the mental quality of life in patients with relapsing-remitting multiple sclerosis, its characteristics were examined in patients treated (n = 25) and non-treated (n = 25) with interferon beta-1b. Using the Time Sampling Diary in which the subjects entered their answers to 8 questions in randomly-chosen time intervals over a period of 14 days the following results were obtained: a) Treated and non-treated patients differed significantly (ANOVA) regarding their mental quality of life expressed as an average of the 5 point response scale with the extreme poles of I feel very bad (1) and I feel very good (5). However, the detected difference was true only of treated and non-treated females and not of males: the treated females felt significantly better subjectively. This finding was also confirmed by configuration-frequency analysis (CFA) of individual response categories. b) From the analysis of the description of how a person feels it is evident that the subjects most often felt tired (29.65%), often experienced pain (16.01%), and joy (16.85%). When comparing the frequency of these states among treated and non-treated females it has been demonstrated that the treated females experience joy more often and sadness less often than non-treated females. The detected differences are interpreted in a way showing that the treatment has a mediating effect upon the mental quality of life: it enabled the treated females to be more active, or to stay in the presence of unknown persons more frequently, which may have resulted in improved values of variables of mental quality of life.
Publication order reference
CEJSH db identifier